Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.60 |
| ▸ | KDM1A | O60341 | 3/20 | 0.59 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.59 |
| ▸ | SMOX | Q9NWM0 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17741878 | 0.81 | MAOA (0.64) | MAOAKDM1ARCOR1SMOXGAA | |
| SCHEMBL17741890 | 0.81 | MAOA (0.61) | MAOAKDM1ARCOR1SMOXHSD17B10 | |
| SCHEMBL9818908 | 0.79 | MAOA (0.58) | MAOAKDM1ARCOR1SMOXHSD17B10 | |
| SCHEMBL17742100 | 0.78 | GAA (0.61) | MAOAKDM1ARCOR1SMOXGAA | |
| SCHEMBL14869738 | 0.77 | HRH4 (0.53) | CYP3A4CYP2C19HSD17B10ALDH1A1POLB | |
| SCHEMBL7397967 | 0.74 | GAA (0.62) | MAOAKDM1ARCOR1SMOXGAA | |
| SCHEMBL17742136 | 0.74 | MAOA (0.52) | MAOAKDM1ARCOR1SMOXCYP3A4 | |
| SCHEMBL20511447 | 0.73 | TSHR (0.52) | CYP3A4CYP2C19HSD17B10ALDH1A1POLB | |
| SCHEMBL10433765 | 0.72 | MAOA (0.62) | MAOAKDM1ARCOR1SMOXGAA | |
| SCHEMBL14869364 | 0.72 | FABP4 (0.47) | CYP3A4CYP2C19HSD17B10ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239882-B2 | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2019-03-26 | — | — | US | disclosed |
| WO-2016073424-A1 | SUBSTITUTED 5-METHYL-[1, 2, 4] TRIAZOLO [1,5-A) PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239882-B2 | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors | PDE12, PDE2A, PDE3A | MAOA 311/4885KDM1A 1041/4885RCOR1 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.